Answers are grounded in this paper and cite their sources.
Reveals PARP2 inhibition enhances antitumor immunity in pancreatic cancer, suggesting a new therapeutic approach.
-driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease.
No takes yet. Share an insight, caveat, or question.
Martínez‐Bosch et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: